Emmes Acquires Casimir to Strengthen Rare Disease Research Capabilities

May 10, 2022

Emmes, a portfolio company of Behrman Capital, has acquired Casimir, a Plymouth, Massachusetts–based CRO specializing in rare disease outcome measures and virtual/remote assessments. The add-on expands Emmes' rare disease center of excellence and brings Casimir's clinical outcomes technology and expertise into Emmes' global service offerings; terms were not disclosed.

Buyers
Emmes, Behrman Capital
Targets
Casimir
Platforms
Emmes
Location
Massachusetts, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.